Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Koji Hashimoto

Clin Mol Hepatol. 2020;26(4):401-410. Published online July 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0072

View: 5672 Download: 152 Web of Science: 7 Crossref: 8

Rui Miguel Martins, João Soeiro Teodoro, Emanuel Furtado, Anabela Pinto Rolo, Carlos Marques Palmeira, José Guilherme Tralhão

Clin Mol Hepatol. 2019;25(2):190-198. Published online March 22, 2019

DOI: https://doi.org/10.3350/cmh.2018.0087

View: 6759 Download: 164 Web of Science: 7 Crossref: 6

Ki Youl Seo, M.D., Il-Hwan Moon, M.D., Kwon Yoo, M.D., Hye Kyung Jung, M.D., Ku Yong Chung, M.D.*, and Kum Ja Choi, M.D.*

Clin Mol Hepatol. 2001;7(4):475-484. Published online January 1, 1970

View: 2010 Download: 17

1 |

Viewed By 5387	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5339	MAFLD: How is it different from NAFLD?
Viewed By 5227	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3910	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3877	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Search